Pipeline update - following an interim analysis the studies with
bifeprunox for the treatment of sch
(Thomson Reuters ONE) - H. Lundbeck A/S (Lundbeck) today announced the joint decision withits partner Solvay Pharmaceuticals, B.V. (Solvay) to stop all jointR&D activities for Solvay's compound bifeprunox in development formaintenance treatment of schizophrenia.The companies made this decision after evaluating the recent resultsfrom an interim analysis of pooled data intended for a possibleextension of the ongoing clinical phase III trial programme. Efficacydata did not support pursuing the existing development strategy ofstabilisation of non-acute patients with schizophrenia. Therefore,Lundbeck and Solvay judge that it would be futile to continue thestudies.The content of this release will have no influence on the LundbeckGroup's financial result for 2009.About bifeprunoxBifeprunox, a partial dopamine and serotonin 5-HT1A agonist designedto stabilize dopamine function in the brain, has been studied in morethan 2,500 patients with schizophrenia in 14 efficacy and safetystudies conducted throughout the world. Solvay is the originator ofthe compound.Lundbeck contactsInvestors: Media:Jacob Tolstrup Mads KronborgDirector, IR & Communication Media Relations+45 36 43 30 79 +45 36 43 28 51Palle Holm OlesenHead of Investor Relations+45 36 43 24 26Magnus Thorstholm JensenInvestor Relations Officer+45 36 43 38 16About LundbeckH. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an internationalpharmaceutical company highly committed to improve the quality oflife for people suffering from central nervous system (CNS)disorders. For this purpose Lundbeck is engaged in the research anddevelopment, production, marketing and sale of pharmaceuticals acrossthe world, targeted at disorders like depression and anxiety,schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson'sdiseases.Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark,and employs today over 5,500 people worldwide. Lundbeck is one of theworld's leading pharmaceutical companies working with CNS disorders.In 2008, the company's revenue was DKK 11.3 billion (approximatelyEUR 1.5 billion or USD 2.2 billion). For more information, pleasevisit www.lundbeck.com.http://hugin.info/130085/R/1331489/315053.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 30.07.2009 - 07:54 Uhr
Sprache: Deutsch
News-ID 4120
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 422 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pipeline update - following an interim analysis the studies with
bifeprunox for the treatment of sch"
steht unter der journalistisch-redaktionellen Verantwortung von
H. Lundbeck A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
